AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2817915
Drug: Aristocort creams
RxNorm normalized name: triamcinolone acetonide Topical Cream [Aristocort]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aristocort creams 0.5%
Trial: 2817915
Drug: Hytone cream
RxNorm normalized name: hydrocortisone / iodoquinol Topical Cream [Vytone]
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hytone cream 1.0%
Trial: 2817915
Drug: Synalar creams
RxNorm normalized name: fluocinolone Topical Cream [Synalar]
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synalar creams 0.01%
Trial: 2817915
Drug: Topicort creams
RxNorm normalized name: desoximetasone Topical Cream [Topicort]
DrugBank: Desoximetasone (DB00547)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topicort creams 0.25%
Trial: 2817915
Drug: Vallisone creams
RxNorm normalized name: betamethasone Topical Cream [Valisone]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vallisone creams 0.1%
Trial: 1215862
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of orciprenaline aerosol
Trial: 21561483
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (SBC and deproteinized bovine bone)
Trial: 15496274
Drug: Growth factor
RxNorm normalized name: Growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth factor priming using filgrastim (G‐CSF) and sagramostim (GM‐CSF)
Trial: 15496274
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment regimens without growth factor priming
Trial: 8009691
Drug: Incision, curettage,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incision, curettage, and suture under antibiotic cover
Trial: 54336
Drug: Standard typhoid
RxNorm normalized name: Typhoid vaccine
DrugBank: Typhoid vaccine (DB14022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard typhoid vaccine (lot 6A)
Trial: 26400262
Drug: Protein mix
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein mix (3×20 g/d) for 4 weeks
Trial: 21312265
Drug: Risedronate 5
RxNorm normalized name: risedronate 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 5 mg/d for 52 weeks
Trial: 17406745
Drug: Gene expression
RxNorm normalized name: Antisense Oligonucleotide Inhibitor Of The Expression Of Superoxide Dismutase 1 Gene
DrugBank: Tofersen (DB14782)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene expression profile assessment for adjuvant therapy decision
Trial: 17406745
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant therapy based on gene expression profile
Trial: 14756386
Drug: Fluconazole 150
RxNorm normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole 150 mg capsule from Laboratório Teuto Brasileiro Ltd.
Trial: 14756386
Drug: Zoltec 150
RxNorm normalized name: Coltec EC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoltec 150 mg capsule from Laboratórios Pfizer Ltd.
Trial: 8081350
Drug: Cranial electrotherapy
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranial electrotherapy stimulation (CES), 45 min daily, 4 days a week for 3 weeks
Trial: 8081350
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (placebo control)
Trial: 782464
Drug: Prednisone plus
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone plus low-dose azathioprine and cyclophosphamide
Trial: 28183580
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (propofol)
Trial: 17230434
Drug: Negative binomial
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative binomial model for treatment analysis
Trial: 11331840
Drug: Dacron-patch closure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacron-patch closure
Trial: 11331840
Drug: Vein-patch closure
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vein-patch closure
Trial: 29409064
Drug: Vardenafil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil (10 mg daily)
Trial: 17162863
Drug: Tramadol (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (oral, two times a day) plus Tobradex and Diclofenac sodium eyedrops (four times a day)
Trial: 10195531
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg intrathecal morphine
Trial: 10195531
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia (systemic morphine)
Trial: 7756098
Drug: Ibuprofen, 400
RxNorm normalized name: Ibuprofen, 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen, 400 mg three times daily for 3 days
Trial: 1518268
Drug: 0.02 microM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 microM methotrexate (MTX) and 2 microM 6-mercaptopurine (6MP) combination treatment
Trial: 1518268
Drug: Intravenous MTX
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous MTX (5 g/m2)
Trial: 1518268
Drug: Intravenous MTX
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous MTX followed by 6MP (1.3 g/m2)
Trial: 4053513
Drug: Intravenous vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous vasopressin (1‐3 mu‐units min‐1 kg‐1)
Trial: 4053513
Drug: Aspirin (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (2.4 g)
Trial: 4053513
Drug: Termination of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Termination of vasopressin infusion
Trial: 17932223
Drug: 9-h modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-h modified release formulation of UK-338,003
Trial: 17932223
Drug: 15-h modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-h modified release formulation of UK-338,003
Trial: 16845959
Drug: Periodontal membrane
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periodontal membrane injection
Trial: 16845959
Drug: Intrapulpal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapulpal injection
Trial: 25331108
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin 1 g daily for 3 days (group A)
Trial: 25331108
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy (group B)
Trial: 16701182
Drug: 4 paravertebral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 paravertebral injections
Trial: 16701182
Drug: 1 paravertebral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 paravertebral injection
Trial: 10607686
Drug: Escalating Dose
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating Dose Regimen (EDR)
Trial: 10607686
Drug: Bulk Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bulk Dose Regimen (BDR)
Trial: 3328638
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment by GPs (Control)
Trial: 30101519
Drug: Nonablative fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonablative fractional laser (NAFL) treatment, 1540-nm, 40-50 mJ per microbeam, applied three times: immediately before surgery, at suture removal, and 6 weeks after surgery.
Trial: 27871563
Drug: Fascia iliaca
RxNorm normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascia iliaca compartment block (FICB) with 30 mL of 0.375% ropivacaine
Trial: 27871563
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (IVF) at 0.5 μg/kg body weight, repeated up to a maximum of 3 doses
Trial: 22541747
Drug: Paroxetine 40
RxNorm normalized name: PARoxetine 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 40 mg tablet formulation (test product)
Trial: 10553738
Drug: Clozapine 900
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine 900 mg/day
Trial: 10553738
Drug: Clozapine 100
RxNorm normalized name: clozapine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine 100 mg/day (Gender effect)
Trial: 10553738
Drug: Clozapine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (all doses)
Trial: 6240223
Drug: trimethoprim-sulfamethoxazole (160-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trimethoprim-sulfamethoxazole (160-800 mg) twice daily for 10 days
Trial: 26845343
Drug: QMF149 (indacaterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QMF149 (indacaterol acetate 150 μg/mometasone furoate 320 μg)
Trial: 26845343
Drug: Indacaterol monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol monotherapy
Trial: 26845343
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate monotherapy
Trial: 18457257
Drug: Nerve growth
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve growth factor (NGF) applied topically, 9000 AU NGF in 100 ml saline solution before operation and injections every other day for one month post-operation
Trial: 18457257
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated with normal saline solution
Trial: 15368601
Drug: rhGH (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (recombinant human growth hormone)
Trial: 11248285
Drug: Tinzaparin 175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinzaparin 175 IU/kg subcutaneous administration
Trial: 9831696
Drug: nisoldipine (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nisoldipine (20-40 mg once daily)
Trial: 9831696
Drug: lisinopril (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril (10-20 mg once daily)
Trial: 9831696
Drug: nisoldipine and
RxNorm normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nisoldipine and lisinopril (compared to each other)
Trial: 7990347
Drug: Leukinferon administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukinferon administered intramuscularly for 10 days (day 1: 3 samples, day 2: 2 ampules, day 3: 1 ampule daily, total 1 x 10(5) U of interferon)
Trial: 2524327
Drug: netilmicin 200
RxNorm normalized name: netilmicin 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: netilmicin 200 mg daily
Trial: 2524327
Drug: netilmicin 200
RxNorm normalized name: netilmicin 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: netilmicin 200 mg + ampicillin 1 g daily
Trial: 23541643
Drug: Dose level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level I: 69 Gy in 30 fractions of 2.3 Gy
Trial: 23541643
Drug: Dose level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level II: 72 Gy in 30 fractions of 2.4 Gy
Trial: 23541643
Drug: Dose level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level III: 75 Gy in 30 fractions of 2.5 Gy
Trial: 19495544
Drug: Oxybutynin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin (2.5 mg) three times per day
Trial: 15181050
Drug: eplerenone 50
RxNorm normalized name: eplerenone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eplerenone 50 mg/d
Trial: 15181050
Drug: eplerenone 100
RxNorm normalized name: eplerenone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eplerenone 100 mg/d
Trial: 15181050
Drug: eplerenone 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eplerenone 200 mg/d
Trial: 15181050
Drug: eplerenone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eplerenone (all doses)
Trial: 9027779
Drug: Simvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (10 mg daily, n = 24)
Trial: 8391513
Drug: SCH 42495
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH 42495 (200 mg, every 12 hours)
Trial: 27259970
Drug: Sodium naproxen
RxNorm normalized name: Naproxen Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium naproxen 550 mg b.i.d. plus rebamipide 100 mg b.i.d.
Trial: 27259970
Drug: Sodium naproxen
RxNorm normalized name: Naproxen Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium naproxen 550 mg b.i.d. plus placebo
Trial: 20142308
Drug: R213129 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R213129 3 mg
Trial: 20142308
Drug: R213129 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R213129 10 mg
Trial: 15763574
Drug: Alcohol (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (24 g ethyl alcohol, 1508 kJ, 405 ml)
Trial: 15763574
Drug: No-alcohol (867
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-alcohol (867 kJ, 405 ml)
Trial: 12046033
Drug: Simvastatin, 20
RxNorm normalized name: Simvastatin, 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin, 20 mg/d for 8 weeks
Trial: 11783153
Drug: Puerarin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Puerarin (600 mg intravenously, once daily for one week)
Trial: 11783153
Drug: Control (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (same treatment as treated group, but without puerarin)
Trial: 2109445
Drug: Pyridostigmine 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine 120 mg orally one hour prior to GHRH (100 micrograms iv)
Trial: 2109445
Drug: GHRH (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH (100 micrograms iv) with pyridostigmine (120 mg)
Trial: 2109445
Drug: GHRH (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH (higher doses) or pyridostigmine (higher doses)
Trial: 27405732
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality treatment (CMT)
Trial: 23692587
Drug: High-dose paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose paracetamol (6 grams daily for three consecutive days)
Trial: 21953763
Drug: HDLI (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDLI (higher demand dose with low constant infusion)
Trial: 21953763
Drug: LDHI (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDHI (lower demand dose and higher constant infusion)
Trial: 18187214
Drug: Atorvastatin 10mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10mg/day
Trial: 17563167
Drug: Telephone-administered supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered supportive emotion focused therapy (T-SEFT)
Trial: 10588412
Drug: Sustained outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained outpatient commitment with higher intensity of outpatient treatment
Trial: 8537594
Drug: A.G.E. dementia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A.G.E. dementia care program
Trial: 24611484
Drug: UP446 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UP446 (500 mg/day)
Trial: 24611484
Drug: naproxen (440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen (440 mg/day)
Trial: 17239062
Drug: Community-based stroke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based stroke prevention programme (eight weekly two-hour sessions)
Trial: 9585772
Drug: Broad spectrum
RxNorm normalized name: Broad spectrum penicillin
DrugBank: Octinoxate (DB09496)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Broad spectrum antimicrobial therapy and operation
Trial: 7896992
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum (2 mg) available to all participants
Trial: 28541285
Drug: Pharmacological challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological challenge of opioid receptor function
Trial: 23637069
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy programme for care home staff to increase activity provision
Trial: 19594087
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g CHO in 400 ml of water
Trial: 19594087
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g aspartam in 100 ml of water (Control)
Trial: 15487740
Drug: Functional-imaging-weighted equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional-imaging-weighted equivalent uniform dose (fEUD) calculation using FDG-PET activity as a surrogate for tumor cell density
Trial: 15487740
Drug: Equivalent uniform
RxNorm normalized name: Eugenia uniflora whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equivalent uniform dose (EUD) calculation assuming uniform tumor cell density
Trial: 11598557
Drug: Misoprostol with
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol with oxytocin infusion
Trial: 7700063
Drug: Cilazapril 1-5
RxNorm normalized name: cilazapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 1-5 mg once daily for 12 weeks
Trial: 7700063
Drug: Cilazapril 0.5-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 0.5-15 mg once daily
Trial: 7700063
Drug: Cilazapril therapy
RxNorm normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril therapy
Trial: 3038254
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg daily for 6 months
Trial: 25639570
Drug: Present-Centered therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Present-Centered therapy (PCT)
Trial: 25639570
Drug: High treatment
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High treatment responders (collapsed across treatments)
Trial: 25639570
Drug: High treatment
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High treatment responders (mid-treatment)
Trial: 25639570
Drug: Thoughts of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoughts of incompetence (high treatment responders)
Trial: 25639570
Drug: Thoughts of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoughts of a dangerous world (high treatment responders)
Trial: 25639570
Drug: Script-associated cortisol
RxNorm normalized name: cortisol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Script-associated cortisol response prior to treatment and reductions in thoughts of incompetence
Trial: 17057622
Drug: Standard monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard monitoring including hormone assays and ultrasound
Trial: 12419788
Drug: High-fiber supplement
RxNorm normalized name: FIBERMED HIGH-FIBER SUPPLEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fiber supplement (13.5 g/day)
Trial: 12419788
Drug: Low-fiber supplement
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fiber supplement (2.0 g/day)
Trial: 10321445
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy change due to inadequate blood pressure control
Trial: 10321445
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy change due to adverse effects
Trial: 10321445
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy change due to patient dissatisfaction
Trial: 10321445
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy change due to non-compliance
Trial: 10321445
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy change due to cost
Trial: 27644137
Drug: ω-3-rich enteral
RxNorm normalized name: budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ω-3-rich enteral nutrition (900 mg of ω-3 fatty acids)
Trial: 27644137
Drug: ω-3-poor enteral
RxNorm normalized name: budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ω-3-poor enteral nutrition (250 mg of ω-3 fatty acids)
Trial: 23359310
Drug: Low-dose naltrexone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose naltrexone (4.5 mg/day)